🧪 European Journal of Medicinal Chemistry [Neurosurgery Wiki]

This page is read only. You can view the source, but not change it. Ask your administrator if you think this is wrong.
===== 🧪 European Journal of Medicinal Chemistry =====

**Abbreviation:** //Eur. J. Med. Chem.//  
**Publisher:** Elsevier (on behalf of the Société de Chimie Thérapeutique)  
**Focus:** Medicinal chemistry, drug design, pharmacology  
**Impact Factor (2024):** ≈ 7.0  
**ISSN:** 0223-5234 (print) / 1768-3254 (online)  
**Access:** Hybrid (open access + subscription)

----

==== 🎯 Scope and Positioning ====

The journal covers a broad range of topics in medicinal chemistry, including:  
  * Small molecule synthesis  
  * Structure–activity relationships (SAR)  
  * Prodrug design  
  * Pharmacodynamics and pharmacokinetics  
  * Occasionally, preclinical pharmacology

**Strength:** Comprehensive platform for chemical innovation with therapeutic aims.  
**Weakness:** Often disconnected from translational or clinical impact. Many articles never progress beyond rodent models or cell lines.

----

==== ⚖️ Scientific Rigor & Methodological Quality ====

^ Area                     ^ Assessment                           ^
| **Peer review**          | Moderate — 3–4 weeks avg. turnaround |
| **Experimental depth**   | Variable — some papers are robust, others exploratory |
| **Reproducibility focus**| Low — protocols often lack standardization |
| **Clinical relevance**   | Frequently speculative, especially in oncology |
| **Bias risk**            | Moderate — high percentage of positive findings, few negative controls |

> //“Hypothesis validation” is often confused with “hypothesis decoration.”//

----

==== 🧠 Strengths for Neurosurgeons or Clinicians ====

  * Good source of first-generation drug candidates, especially prodrugs, enzyme inhibitors, or hypoxia-targeted agents.  
  * May offer novel molecular scaffolds applicable in neuro-oncology or neuromodulation.

----

==== ⚠️ Limitations ====

  * No clinical trials — not designed for translational medicine.  
  * Heavy emphasis on chemical novelty over biological significance.  
  * Often lacks:  
    - Biodistribution data  
    - Blood–brain barrier studies  
    - Disease-specific models (e.g., glioblastoma, spinal cord tumors)

> //“A journal more interested in the molecule than in the patient.”//

----

==== 🧨 Bottom Line (Neurosurgery Wiki Verdict) ====

> **European Journal of Medicinal Chemistry is where promising molecules are born — and too often, where they also die.**  
> Excellent for spotting chemical innovation, but limited use for clinicians unless preclinical findings are confirmed elsewhere.